Search

Your search keyword '"Friederike Klenner"' showing total 2 results
Start Over Author "Friederike Klenner" Journal pulmonary circulation
2 results on '"Friederike Klenner"'

1. Real-life data on Selexipag for the treatment of pulmonary hypertension

Author

Michaela Barnikel, Nikolaus Kneidinger, Friederike Klenner, Andrea Waelde, Paola Arnold, Torben Sonneck, Jürgen Behr, Claus Neurohr, and Katrin Milger

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701, Diseases of the respiratory system, RC705-779
Abstract

Selexipag is an orally available selective IP prostacyclin-receptor agonist licensed since 2016 for the therapy of pulmonary arterial hypertension (PAH). We aimed to describe real-life data of patients with pulmonary hypertension (PH) treated with selexipag. We analyzed all patients initiated with selexipag from July 2016 to April 2018 at the Department of Internal Medicine V, University of Munich. Non-invasive and invasive parameters corresponding to the risk assessment were collected at baseline and follow-up (FU). Furthermore, we recorded tolerability. Twenty-six patients were treated with selexipag, of whom 23 had PAH and three had chronic thromboembolic PH. At baseline, most patients were in function class (FC) II or III (42% and 54%, respectively). All patients were under medical treatment for PH, mostly dual therapy (92%). One or more side effects were noted in 19 patients, while seven reported no side-effects. FU assessment was available in 20 patients after 149 ± 80 days of treatment. Nt-proBNP (median, baseline 1641 pg/mL, FU 1185 pg/mL, P = 0.05) and PVR (mean ± SD, baseline 8.5 ± 4.3 WU, FU 5.6 ± 1.1 WU; P

Published
2019
Full Text
View/download PDF

2. Real-life data on Selexipag for the treatment of pulmonary hypertension

Author

Claus Neurohr, Michaela Barnikel, Andrea Waelde, Katrin Milger, T Sonneck, Nikolaus Kneidinger, Jürgen Behr, Friederike Klenner, and P Arnold

Subjects
Pulmonary and Respiratory Medicine, Agonist, lcsh:RC705-779, medicine.medical_specialty, lcsh:Diseases of the circulatory (Cardiovascular) system, medicine.drug_class, business.industry, Hemodynamics, lcsh:Diseases of the respiratory system, Selexipag, medicine.disease, Real life data, Pulmonary hypertension, chemistry.chemical_compound, Tolerability, chemistry, lcsh:RC666-701, Internal medicine, Cardiology, medicine, Risk assessment, business, Research Article
Abstract

Selexipag is an orally available selective IP prostacyclin-receptor agonist licensed since 2016 for the therapy of pulmonary arterial hypertension (PAH). We aimed to describe real-life data of patients with pulmonary hypertension (PH) treated with selexipag. We analyzed all patients initiated with selexipag from July 2016 to April 2018 at the Department of Internal Medicine V, University of Munich. Non-invasive and invasive parameters corresponding to the risk assessment were collected at baseline and follow-up (FU). Furthermore, we recorded tolerability. Twenty-six patients were treated with selexipag, of whom 23 had PAH and three had chronic thromboembolic PH. At baseline, most patients were in function class (FC) II or III (42% and 54%, respectively). All patients were under medical treatment for PH, mostly dual therapy (92%). One or more side effects were noted in 19 patients, while seven reported no side-effects. FU assessment was available in 20 patients after 149 ± 80 days of treatment. Nt-proBNP (median, baseline 1641 pg/mL, FU 1185 pg/mL, P = 0.05) and PVR (mean ± SD, baseline 8.5 ± 4.3 WU, FU 5.6 ± 1.1 WU; P

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results